James F. Oliviero III

CIK: 0001434718

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (45.5%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (36.4%)

Compensation grants

Other (G, F, J, C, D, …)2 (18.2%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

NVCT

Nuvectis Pharma, Inc.

Director

CKPT

Checkpoint Therapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (11 total)

NVCT
Nuvectis Pharma, Inc.
Jun 11, 2026
Award(A)
Direct
35K shares-
NVCT
Nuvectis Pharma, Inc.
Jun 12, 2025
Award(A)
Direct
30K shares-
CKPT
Checkpoint Therapeutics, Inc.
May 30, 2025
Tender Offer(U)
Direct
3.8M shares-
CKPT
Checkpoint Therapeutics, Inc.
Apr 2, 2025
Sale(S)
Direct
15.1K shares at avg. $4.04$61K
CKPT
Checkpoint Therapeutics, Inc.
Feb 10, 2025
Sale(S)
Direct
10.3K shares at avg. $3.15$33K
CKPT
Checkpoint Therapeutics, Inc.
Feb 7, 2025
Sale(S)
Direct
9.2K shares at avg. $3.41$31K
CKPT
Checkpoint Therapeutics, Inc.
Jan 30, 2025
Award(A)
Direct
1.5M shares-
CKPT
Checkpoint Therapeutics, Inc.
Dec 20, 2024
Gift(G)
Direct
900K shares-
CKPT
Checkpoint Therapeutics, Inc.
Dec 19, 2024
Sale(S)
Direct
220.2K shares at avg. $3.38$744K
CKPT
Checkpoint Therapeutics, Inc.
Dec 18, 2024
Sale(S)
Direct
602.2K shares at avg. $3.87$2.3M
CKPT
Checkpoint Therapeutics, Inc.
Dec 13, 2024
Award(A)
Direct
2.1M shares-

		Type	Shares	Price		Ownership
Jun 11, 2026	NVCT Nuvectis Pharma, Inc.	Award(A)	35,000	-	$0	Direct
Jun 12, 2025	NVCT Nuvectis Pharma, Inc.	Award(A)	30,000	-	-	Direct
May 30, 2025	CKPT Checkpoint Therapeutics, Inc.	Tender Offer(U)	3,759,929	-	-	Direct
Apr 2, 2025	CKPT Checkpoint Therapeutics, Inc.	Sale(S)	15,090	$4.04	$60,964	Direct
Feb 10, 2025	CKPT Checkpoint Therapeutics, Inc.	Sale(S)	10,331	$3.15	$32,543	Direct
Feb 7, 2025	CKPT Checkpoint Therapeutics, Inc.	Sale(S)	9,233	$3.41	$31,485	Direct
Jan 30, 2025	CKPT Checkpoint Therapeutics, Inc.	Award(A)	1,500,000	-	$0	Direct
Dec 20, 2024	CKPT Checkpoint Therapeutics, Inc.	Gift(G)	900,000	-	$0	Direct
Dec 19, 2024	CKPT Checkpoint Therapeutics, Inc.	Sale(S)	220,230	$3.38	$744,377	Direct
Dec 18, 2024	CKPT Checkpoint Therapeutics, Inc.	Sale(S)	602,167	$3.87	$2,330,386	Direct
Dec 13, 2024	CKPT Checkpoint Therapeutics, Inc.	Award(A)	2,077,700	-	$0	Direct

1-11 of 11 transactions

About Oliviero James F III

Oliviero James F III (SEC CIK 0001434718) files insider reports with the SEC as Director of Nuvectis Pharma, Inc. (NVCT) and CEO, President and Director of Checkpoint Therapeutics, Inc. (CKPT).

Signal8 holds 8 ownership filings by Oliviero James F III, all Form 4s, filed between Dec 17, 2024 and Jun 12, 2026. Those filings report 11 transactions, from Dec 13, 2024 to Jun 11, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Oliviero James F III's filings is in FORT LEE, NJ.

Recent filings by Oliviero James F III

Jun 11, 2026: Grant or award of NVCT shares (Form 4, code A).
Jun 12, 2025: Grant or award of NVCT shares (Form 4, code A).
May 30, 2025: Tender of shares transaction of CKPT shares (Form 4, code U).
Apr 2, 2025: Open-market sale of CKPT shares (Form 4, code S).
Feb 10, 2025: Open-market sale of CKPT shares (Form 4, code S).

Other insiders filing for Nuvectis Pharma, Inc. (NVCT)

Carson Michael J., Vice President, Finance
Mosseri Marlio Charles, 10% Owner
BENTSUR RON, Chairman & CEO
Hoberman Kenneth, Director
Sanchez Juan, Director
Kaplan Matthew L., Director

How to read Form 4 transaction codes